tailieunhanh - Báo cáo y học: "Inhibition of NFκB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Inhibition of NFκB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation. | Journal of Inflammation BioMed Central Open Access Short Report Inhibition of NFkB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation Rangan Maitra 1 Melissa A Porter1 Shan Huang2 and Brian P Gilmour1 Address 1Center for Organic and Medicinal Chemistry The Research Triangle Institute Research Triangle Park NC 27709 USA and 2Department of Chemistry Duke University Box 90354 Durham NC 27708-0354 USA Email Rangan Maitra - rmaitra@ Melissa A Porter - mporter@ Shan Huang - Brian P Gilmour - bgilmour@ Corresponding author Published 13 May 2009 Received 7 November 2008 Journal of Inflammation 2009 6 15 doi l476-9255-6-l5 Accepted I3 May 2009 This article is available from http content 6 l l5 2009 Maitra et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Cystic Fibrosis CF is one of the most common autosomal genetic disorders in humans. This disease is caused by mutations within a single gene coding for the cystic fibrosis transmembrane conductance regulator CFTR protein. The phenotypic hallmark of CF is chronic lung infection and associated inflammation from opportunistic microbes such as Pseudomonas aeruginosa PA Haemophilus influenzae and Staphylococcus aureus. This eventually leads to deterioration of lung function and death in most CF patients. Unfortunately there is no approved therapy for correcting the genetic defect causal to the disease. Hence controlling inflammation and infection in CF patients are critical to disease management. Accordingly anti-inflammatory agents and antibiotics are used to manage chronic inflammation and infection in CF patients. However most of the antiinflammatory agents in